Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
Related Experiment Video
Updated: Aug 8, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
A M Schmidt1, S D Yan, J L Wautier
1Division of Surgical Science, Department of Surgery, College of Physicians & Surgeons of Columbia University, New York, NY 10032, USA.
Abstract:
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
Insights
The receptor for advanced glycation end products (RAGE) plays a key role in chronic inflammatory diseases. Blocking RAGE signaling significantly reduced atherosclerosis in diabetic mice, independent of blood sugar or lipid levels.
Area of Science:
- Cellular biology
- Immunology
- Pathology
Background:
- Receptor for advanced glycation end products (RAGE) is an immunoglobulin superfamily member involved in various pathological processes.
- RAGE ligands include advanced glycation end products (AGEs) and amyloid beta peptide, implicated in diabetes, oxidative stress, renal failure, amyloidoses, and Alzheimer disease.
Purpose of the Study:
- To investigate the role of RAGE in diabetic atherosclerosis.
- To evaluate the therapeutic potential of blocking RAGE signaling in a mouse model of atherosclerosis.
Main Methods:
- Utilized a mouse model of accelerated atherosclerosis associated with diabetes.
- Administered a soluble, truncated form of RAGE to block cell surface RAGE.
- Assessed the impact on vascular lesion formation, plasma lipids, and glycemia.
Main Results:
- Blockade of cell surface RAGE completely suppressed enhanced vascular lesion formation in diabetic/atherosclerotic mice.
- The amelioration of atherosclerosis occurred independently of changes in plasma lipids or glycemia.
- This suggests a lipid- and glycemia-independent mechanism involving RAGE-ligand interaction contributes to atherogenesis.
Conclusions:
- Sustained RAGE expression and ligand interaction can lead to chronic cellular activation and tissue damage.
- RAGE signaling is a significant contributor to atherogenesis in the context of diabetes.
- Targeting RAGE may offer a therapeutic strategy for chronic inflammatory disorders, including diabetic vasculopathy.
More Related Videos
06:05Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
Published on: May 2, 2025
14:10A Microfluidic System for Modeling Endothelial Dysfunction under Combined Physiological Pulsatile Shear Stress and Oscillatory Hyperglycemia
Published on: May 12, 2026
Related Concept Videos
Peripheral Artery Disease I: Introduction
Type II Diabetes II: Pathophysiology
Diabetic Foot Ulcer
Diabetic Retinopathy
Diabetic Nephropathy
Diabetic Neuropathy